Skip to Main Content

Paper Details

First-generation oral antivirals against SARS-CoV-2.
Clin Microbiol Infect
22
2022
COVID-19, Molnupiravir, SARS-, SARS-CoV, SARS-CoV-2, immunosuppressed, molnupiravir, nirmatrelvir, patients, ritonavir, severe acute respiratory syndrome coronavirus
Author NameAffiliation
Parham SendiInstitute for Infectious Diseases, University of Bern
Rajesh T GandhiMassachusetts General Hospital, Harvard Medical School
  • 1 - 2

Datasets

PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink
PubMedCitations and abstracts of biomedical literatureLink